Alirocumab

Praluent

PCSK9 Inhibitor

NADAC/unit $258.0650

No Shortage Tier 1: 2.4% PA Req: 26.1%

Alirocumab dramatically lowers LDL cholesterol by blocking the PCSK9 protein.

vs. brand Praluent: Generic saves up to -2481% per unit

Covered Lives

Explore in the Ecosystem

rxsaver.aiCompare prices for Alirocumab drfinder.aiFind doctors who prescribe Alirocumab rxpbm.aiPBM spread analysis for Alirocumab clinicalrx.aiClinical profile: Alirocumab

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.